Article citationsMore>>

Naci, H., Basu, S. and Yudkin, J.S. (2015) Preventing Cardiovascular Events with Empagliflozin: At What Cost? The Lancet Diabetes & Endocrinology, 3, 931.
http://dx.doi.org/10.1016/S2213-8587(15)00439-8

has been cited by the following article:

• TITLE: Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!

  AUTHORS: Udaya M. Kabadi

  KEYWORDS: Review Paper

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.6 No.2, April 20, 2016

  ABSTRACT: It was interesting to read the recent article regarding the efficacy of Empagliflozin in reducing all cause and cardiovascular mortality [1]. Superficially, the report appears to be very promising. However, the methodology, the results and the conclusions deserve and need further scrutiny and validation for several reasons.